Comparison Of Carbamazepine Research Articles

Comparison of carbamazepine alone and in combination with baclofen in trigeminal neuralgia

Introduction: Trigeminal neuralgia is a type of neuropathic facial pain that is characterized by unilateral paroxysmal pain that affects one or more trigeminal nerve divisions and is brought on by unimportant stimuli. People over the age of 40 are more likely to get it, and women are more frequently affected than males. Trigeminal neuralgia has been treated with a variety of drugs, including carbamazepine, oxcarbazepine, baclofen, lamotrigine, levetiracetam, gabapentin, sodium valproate, botulinum toxin-A injection, and surgical. OBJECTIVES: The current study's objective was to assess the efficacy of carbamazepine in treating trigeminal neuralgia in individuals both on its own and in combination with baclofen. METHODS: A randomized control trial was conductedat Khyber College of Dentistry and Peshawar Dental College among the patients of trigeminal neuralgia presenting to OPD. Total 60patients were randomly selected into two groups, each group had 30 patients.Carbamazepine was given to the Group A in the dose range of 300-600mg TDSwhereas, Carbamazepine 300mg TDS along with Baclofen in the dose range of 10-20 mg B.D was given to Group B. The two groups were given the drugs for a period of thirty days. The data was collected through a self-structuredquestionnaire.

EHMTI-0355. Comparison of carbamazepine and oxcarbazepine tolerability in patients with trigeminal neuralgia

Little work has been done around the adverse events profile (AEP) of drugs used to treat trigeminal neuralgia (TN). TN patients are often unaware of significant side effects associated with pharmacotherapy.

Comparison of carbamazepine and lithium in treatment of bipolar disorder: A systematic review of randomized controlled trials

To review data from randomized controlled trials (RCTs) assessing the comparative efficacy of carbamazepine and lithium in treatment of acute manic and maintenance phase of bipolar disorder (BD). RCTs were identified through a search strategy that included: electronic databases, reference cross-checking, hand search of non-indexed publications, and book chapters on the treatment of BD comparing carbamazepine with lithium. Outcomes investigated were antimanic effect, trial withdrawal, relapse, hospitalization, need for rescue medication, and presence of adverse effects. Selection of studies and data analysis were performed independently by authors. Whenever possible, data from trials were combined through meta-analyses. Relative risks (RR) were estimated for dichotomous data. In acute mania, carbamazepine was similar to lithium on the following outcomes: trial withdrawal due to adverse effects, number of participants with at least one adverse effect, improvement in the Clinical Global Impression (CGI). In acute mania, carbamazepine was associated with fewer trial withdrawals. In maintenance treatment, carbamazepine was similar to lithium in relapses and hospitalization, but there were fewer trial withdrawals due to adverse effects on lithium. This review suggests that carbamazepine might be comparable to lithium in terms of efficacy and safety, and therefore a valuable option in the treatment of both manic and maintenance phases.

N-3 fatty acids (eicosapentanoic and docosahexanoic acids) in epilepsy and for the prevention of sudden unexpected death in epilepsy

As described in this journal, Bromfield et al. and Yuen et al. tested the hypothesis that n-3 fatty acids may reduce seizures [ 1 Bromfield E. Dworetzsky B. Huwitz S. et al. A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav. 2008; 12: 187-190 Abstract Full Text Full Text PDF PubMed Scopus (83) Google Scholar , 2 Yuen A.W. Sander J.W. Fluegel D. et al. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav. 2005; 7: 253-258 Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar ]. This is important work, founded in sound science. It is known that eicosapentanoic acid reduces the frequency of hippocampal pyramidal neuron firing rates [ [3] Xiao Y. Li X. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res. 1999; 846: 112-121 Crossref PubMed Scopus (114) Google Scholar ]. Furthermore, n-3 fatty acids reduce the number and increase the latency of pentylenetetrazole- and FeCl3-induced seizures, reduce seizure severity in rodents, and improve cognitive recovery after acute seizures [ 4 Yehuda S. Carasso R. Mostofsky D. Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. Eur J Pharmacol. 1994; 254: 193-198 Crossref PubMed Scopus (121) Google Scholar , 5 Voskuyl R. Vregdenhil M. Kang J. et al. Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model. Eur J Pharmacol. 1998; 341: 145-152 Crossref PubMed Scopus (121) Google Scholar , 6 Rabinovitz S. Mostofsky D. Yehuda S. Anticonvulsant efficiency, behavioral performance, and cortisol levels: a comparison of carbamazepine (CBZ) and a fatty acid compound (SR-3). Psychoneuroendocrinology. 2004; 29: 113-124 Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar ]. Moreover, in an important discovery recently reported in this journal, Ferrari et al. found that n-3 fatty acids prevent or reduce hippocampal neuronal injury after status epilepticus [ [7] Ferrari D. Cysneiros R.M. Scorza C. et al. Neuroprotective activity of omega-3 fatty acids against epilepsy-induced hippocampal damage: quantification with immunohistochemical for calcium-binding proteins. Epilepsy Behav. 2008; 13: 36-42 Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar ].

Comparison of carbamazepine and oxcarbazepine effects on aminothiol levels

The aim of our study was to investigate the effects of carbamazepine (CBZ) and oxcarbazepine (OXCBZ) on aminothiol levels, including homocysteine (Hcy), cysteine, and cysteinylglycine, in chronically treated patients. Epileptic patients receiving CBZ or OXCBZ were recruited as part of routine clinical practice. Demographic data and concomitant medications were recorded from the patient medical file. Sixty patients were included in the study; 30 patients were treated with CBZ and 30 with OXCBZ. Median Hcy level was significantly higher in CBZ-treated patients (20.6 micromol/l) than in OXCBZ-treated patients (14.0 micromol/l, p < 0.0001). No correlation was evidenced between antiepileptic drugs or metabolite levels and Hcy levels for each group. Less change observed with OXCBZ compared with CBZ on aminothiol levels could constitute an advantage for OXCBZ treatment in patients with other factors influencing Hcy levels and/or at high risk for cardiovascular diseases.

Anticonvulsant efficiency, behavioral performance and cortisol levels: a comparison of carbamazepine (CBZ) and a fatty acid compound (SR-3)

The role of fatty acids (FA) and their impact on nervous system activity and immune function has attracted much attention. The interest extends beyond a basic understanding of the potential role exerted by FA on the neuronal membrane and its properties, to the implications and clinical significance for many neurological disorders. This is especially true for epilepsy, where many conventional anticonvulsant preparations carry undesired side effects, and a significant number of patients remain refractory to the drug treatment. We report on a comparative examination in rats of carbamazepine (CBZ) and SR-3 (a fatty acid compound) with respect to seizure control efficiency, as well as protective features against cognitive impairment and cortisol level elevation. With pentylenetetrazol (PTZ) induced seizures pre-treated by CBZ, or SR-3, both CBZ and SR-3 were equally effective in providing seizure control and both were superior to the saline control. However SR-3 provided greater protection in Morris Water Maze performance and control of cortisol level elevation.

Comparison of Carbamazepine and Lithium in the Prophylaxis of Bipolar Disorders

This meta-analysis assessed the equipotency of carbamazepine and lithium prophylaxis in bipolar disorder. We selected only randomised, double-blind, controlled studies comparing carbamazepine with lithium from a manual and computerised search, and subjected them to a quality inventory. Their statistical results were weighted by their quality score and combined. Four studies met our criteria, yielding, overall, P = 0.15. This result is not straightforward because the studies showed significant heterogeneity (P < 0.01). Differences in statistical power and sensitivity of outcome measure explain this heterogeneity and the conflicting results of the studies. Therefore, the prophylactic efficacy of carbamazepine remains questionable.